Shanghai, China, July 16, 2025 — The World Health Organization (WHO) and its Global Accelerator for Paediatric Formulations network (GAP-f) have recently released the "Report of the Meeting on Optimizing Pediatric Drugs for Respiratory Syncytial Virus (PADO-RSV)." Ziresovir (10 mg), an innovative anti-respiratory syncytial virus (RSV) drug developed by Shanghai Aike 100 Biomedical Technology Co., Ltd. ("ArkBio"), has been officially included in the WHO’s PADO-RSV Priority List for the treatment of RSV in children. Ziresovir is the world's first and only antiviral treatment for RSV to be included in this list. This marks the first time that a Chinese-developed anti-RSV drug has been added to the WHO/GAP-f pediatric drug optimization priority list, signifying international recognition from authoritative health organizations of ArkBio's innovative achievements in pediatric anti-infective drugs and highlighting the accomplishments and growing influence of Chinese innovative drugs in the global public health arena.

Read the Original Text

July 23, 2025, San Diego & Shanghai – Sirius Therapeutics today announced that its next-generation siRNA therapy, SRSD107, has been approved by the European Medicines Agency (EMA) to proceed with Phase II clinical trials. SRSD107 is a next-generation siRNA therapy specifically targeting anticoagulant Factor XI, intended for the prevention and treatment of thromboembolic diseases. This approval marks a significant regulatory milestone for the program and paves the way for clinical studies to be conducted across multiple European countries. The development of SRSD107 is part of a strategic collaboration between Sirius Therapeutics and CRISPR Therapeutics, both committed to advancing innovative therapies in the field of cardiovascular and coagulation-related diseases.

Read the Original Text

Recently, the "Safe, Efficient, and Low-Recurrence Oral New Drug for Inflammatory Bowel Disease" (PTT-621) project submitted by Beijing Yanming Biotechnology Co., Ltd. has been successfully approved for the 2025 National Key Research and Development Program's Disruptive Technology Innovation Key Special Project.

Beijing Yanming Biotechnology Co., Ltd.'s newly approved project, PTT-621, is an oral ALPK1 small molecule inhibitor drug based on a novel target and mechanism, intended for the treatment of inflammatory bowel disease (IBD).

The approval of this key special project under the National Key R&D Program for Disruptive Technological Innovation marks that Beijing Yanming Biotechnology Co., Ltd. has gained national-level recognition for its technological breakthroughs in the life and health sector. This is a high affirmation of Yanming Biotechnology's innovative R&D capabilities and the strategic value of the project. Yanming Biotechnology will leverage the support from this special project to accelerate the R&D process, striving to achieve technological breakthroughs and transformation applications as soon as possible, contributing to seizing the forefront of life science and serving major national strategic needs.

Read the Original Text

Recently, the successful acquisition of the third-phase base in Quzhou by Tuoxi Technology marks a key advancement in its strategic layout in the high-end polymer materials field. The three blueprints planned by the company — the headquarters base, R&D base, and production base — are turning into a beautiful reality. Currently, Tuoxi Technology's COC product strength has reached the top position in China, with a 100% market share domestically. Several reserve technologies rank among the best internationally, making it an important engine driving the upgrading of China’s high-end polymer materials industry. Focusing on the R&D and manufacturing of cutting-edge materials like COC, Tuoxi Technology continues to shine in key national development areas such as precision optics, life sciences, integrated circuits, and semiconductors. This project is expected to involve a total investment of 1.5 billion yuan, with an annual sales revenue exceeding 5 billion yuan after production begins.

Read the Original Text

On July 2, 2025, the National Health Commission officially announced the approval of Weikang Probiotics Bifidobacterium animalis subsp. lactis BLa80 (Bifidobacterium animalis subsp. lactisBLa80) has been included in the "List of Bacterial Strains Permitted for Use in Infant and Toddler Foods." Weikang Probiotic BLa80 has become the first bacterial strain in mainland China to be listed for infants and toddlers, marking a "zero breakthrough" in the field of domestically developed bacterial strains for infants and toddlers in China.

Read the Original Text

On March 13, 2025, Salus Medical's wholly-owned subsidiary, Shanghai Salus Life Science Co., Ltd. (referred to as "Salus Life"), held a grand opening ceremony for its R&D and production headquarters base in Baoshan High-Tech Zone. In just over three months, more good news came from Shanghai: the self-developed Saluseq Nimbo low-throughput sequencer entered the stage of scaled production and began full shipments. This breakthrough injected Salus' unique technical momentum and innovative vitality into fields such as clinical testing, pathological diagnosis, and forensic identification in East and North China.

Read the Original Text

Suzhou, China, July 3, 2025 — CANbridge Pharmaceuticals Inc. ("CANbridge", stock code "1228.HK"), a leading global biopharmaceutical company in China focusing on rare diseases and committed to the research, development, and commercialization of innovative therapies, announced today that Gorining®, approved for marketing on May 13 for long-term enzyme replacement therapy in patients aged 12 years and above with Type I and Type III Gaucher disease, has been prescribed for the first time at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine. This marks the official entry into clinical application of the first domestically developed enzyme replacement drug in China.

Read the Original Text

On July 2, 2025, MicroSynth's production of allulose officially received the administrative approval from the National Health Commission as a new food ingredient, becoming the first company in China to gain approval for allulose production and the only enterprise approved through a bio-fermentation process (Approval No.: National Health Commission Announcement on D-allulose and 20 Other "Three New Foods" [2025] No. 4). This approval marks the first case in China where a new food ingredient produced using synthetic biotechnology — the AS10 strain direct fermentation method for producing allulose — has been authorized.

Read the Original Text

On July 15, Sino Biopharm (01177.HK) announced that it plans (through the buyer) to acquire 95.09% of Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. for a consideration of no more than US$950.92 million. Excluding Lixin Pharmaceutical’s estimated cash and bank deposits of approximately US$450 million on the closing date, the net payment to be made by the buyer for the acquisition is approximately US$500.9 million. Previously, Sino Biopharm already held 4.91% equity in Lixin Pharmaceutical.

Read the Original Text

Microhealth Probiotics Bifidobacterium animalis subsp. lactis BLa80 (Bifidobacterium animalis subsp. lactisBLa80), as the first infant strain developed in China, has successfully passed both the self-affirmed GRAS and FDA GRAS certifications, becoming the first strain in China to achieve the true "Dual GRAS" certification. This "Dual GRAS" certification fully verifies the safety and unique advantages of BLa80, while also demonstrating the focus and deep cultivation of Weikang Probiotics in the field of microbial research, as well as its firm steps and significant achievements in joining the international forefront.

Read the Original Text

Recently, JINGFENG Medical® successfully won the bid for the procurement project of Beijing Shijitan Hospital, Capital Medical University, marking that the cumulative domestic orders for JINGFENG® endoscopic robots (including multi-port and single-port) have broken through the milestone of 40 units. This significant milestone not only demonstrates the increasing market recognition of surgical robots produced in China, but also highlights the strong development momentum of JINGFENG Medical® in the commercialization of high-end medical equipment.

Read the Original Text

Recently, Qianglian Zhichuang (Beijing) Technology Co., Ltd. ("Qianglian Zhichuang®") and Philips (China) Investment Co., Ltd. ("Philips") officially signed a Memorandum of Cooperation. Both parties reached a consensus to explore collaboration in building an AI interventional treatment ecosystem platform, promoting the UKnow® neuro solutions, joint marketing, and future in-depth cooperation in the stroke field. This collaboration will drive innovation in clinical procedures and the expansion of high-quality medical resources, enabling more patients to access premium medical services.